Specialist
Former Head at ConvaTec Group plc
Agenda
- Update on the European wound care market and competitive landscape, including Coloplast (CSE: COLO B), ConvaTec (LON: CTEC), Molnlycke Health, 3M (NYSE: MMM) and Smith & Nephew (LON: SN)
- Differentiation levels among wound care products
- Healthcare budgets and wound care allocations
- The future of wound care, including telemedicine and remote consultations
Questions
1.
How is the wound care patient population potentially trending? How would you segment the market?
2.
How do you think the acute and chronic buckets will trend? What are the core drivers behind potential patient population growth there?
3.
How are players recuperating from coronavirus as the vaccine roll-out and recovery within hospitals progresses?
4.
Which players were more negatively affected by the complete cut of elective surgery in some countries due to their greater reliance on post-operative procedures?
5.
Could you quantify the reduction in chronic-wound patients presenting to the healthcare system throughout coronavirus?
6.
What are your thoughts on pent-up demand within wound care? Where is it present? I know that Coloplast hasn’t included any significant pent-up demand in its guidance for 2021.
7.
What is yet to be done around using digital tools, platforms and customer interfaces? Coronavirus has caused an uptick in this, and I know ConvaTec said in the 2020 annual results that there’s a lot more to invest in here.
8.
You’ve mentioned patient population is increasing across various wound care buckets. How are hospital budgets for this segment trending alongside the patient population?
9.
How is the healthcare system able to recruit wound care staff? Are there sufficient levels? You mentioned earlier the problem around carers being seconded to COVID-19 vaccination programmes.
10.
Can you quantify what percentage of wound care treatments are done by a district nurse, a viability nurse or similar in the UK market?
11.
A lot of players are focused on investing in training and education and on trying to create an easier understanding of wound care. How successful would you say these efforts have been? What do you think have been the pitfalls to this increased training and education?
12.
What’s the cost-savings potential with the inclusion of remote patient monitoring and telemedicine? I’ve read reports of up to 50% cost savings. Do you think this is accurate? Where will the key cost savings come from?
13.
What time scale do you expect for the adoption of telemedicine? Are there any telemedicine companies that wound care players could partner up with to help bolster their positions in the market?
14.
Which major player do you think has the best strategy for driving the outcome-based future of wound care you mentioned?
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited
